Speaker(s): 

Gretchen Urban, MS, CGC, Genetic Counselor II, Geisinger, has nothing to disclose.

Dr. Alexander Chang, MD, Physician of Nephrology, Geisinger, discloses the following: 1. Novartis ["Research Grant"] 2. Boehringer-Ingelheim ["Research Grant"] 3. Bayer ["Research Grant"] 4. Vertex ["Research Grant"]).

Hashim Abbas, MD, Physician of Nephrology, Geisinger, has nothing to disclose.

 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

  1. Describe clinical features of Tuberous Sclerosis Complex (TSC)  
  2. Discuss management of TSC over the lifetime
  3. Examine a genomic ascertained TSC cohort through case presentation

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Juliann Savatt, MS, LCGC, Melissa Kelly, MS, LCGC, Marc Williams, MD, and Cara McCormick, MPH have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose: Christen Mowad, MD, Alison Mowery, DNP, CRNP

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None

Session date: 
06/08/2026 - 12:00pm to 1:00pm EDT
Location: 
Virtual via Microsoft Teams
Danville, PA 17822
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation Credit
Please login or register to take this course.